Celltrion submits marketing authorization for CT-P6 SC (Herzuma subcutaneous) in Korea; Phase 1 success signals expanded breast cancer treatment options and enhanced enterprise value
On May 28, 2026, Celltrion submitted a marketing authorization application to the Ministry of Food and Drug Safety (MFDS) for CT-P6 SC, a subcutaneous formulation of its trastuzumab biosimilar Herzuma.
The application targets early-stage and metastatic breast cancer, based on a Phase 1 trial involving 203 healthy male subjects.
The trial demonstrated pharmacokinetic equivalence (90% CI for AUC0-inf and Cmax within 80%-125%) compared to Herceptin SC, with similar safety and immunogenicity profiles.
Treatment-emergent adverse events occurred in about 89.5% of subjects, mostly mild to moderate, with no serious adverse events reported.
If approved, Celltrion expects to expand patient access and convenience through the SC formulation, complementing the existing IV version and potentially increasing market share.
The company plans to file for approvals in other countries sequentially after this Korean application.
[AI Comprehensive Analysis]This application represents a strategic expansion of Celltrion's biosimilar portfolio, with robust clinical data supporting a high likelihood of approval. However, considering regulatory timelines and competitive dynamics (e.g., originator SC formulation), the event is more likely to contribute to mid-to-long-term value enhancement rather than short-term price surges.
KOSPI Filing Information
Filing: Major Management Matters Related to Investment Judgment (CTP6 SC(Herjuma Subcutaneous Injection Formulation) Korean Product Approval Application)